These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 1352109)
41. Contribution of new technologies to characterization and prediction of adverse effects. Rouquié D; Heneweer M; Botham J; Ketelslegers H; Markell L; Pfister T; Steiling W; Strauss V; Hennes C Crit Rev Toxicol; 2015 Feb; 45(2):172-83. PubMed ID: 25615431 [TBL] [Abstract][Full Text] [Related]
42. Total allowable concentrations of monomeric inorganic aluminum and hydrated aluminum silicates in drinking water. Willhite CC; Ball GL; McLellan CJ Crit Rev Toxicol; 2012 May; 42(5):358-442. PubMed ID: 22512666 [TBL] [Abstract][Full Text] [Related]
43. The use of the dog in toxicity tests on pharmaceutical compounds. Parkinson C; Grasso P Hum Exp Toxicol; 1993 Mar; 12(2):99-109. PubMed ID: 8096722 [TBL] [Abstract][Full Text] [Related]
44. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies. Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943 [TBL] [Abstract][Full Text] [Related]
45. International Conference on Harmonisation: guidance on testing for carcinogenicity of pharmaceuticals. Notice. Food and Drug Administration, HHS. Fed Regist; 1998 Feb; 63(35):8983-6. PubMed ID: 12269370 [TBL] [Abstract][Full Text] [Related]
46. Research and development of new medicines. Ankier SI; Warrington SJ J Int Med Res; 1989; 17(5):407-16. PubMed ID: 2680676 [TBL] [Abstract][Full Text] [Related]
47. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products. Lewis RM; Cavagnaro J Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910 [TBL] [Abstract][Full Text] [Related]
48. Anticancer Drug Development: The Way Forward. Connors T Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985 [TBL] [Abstract][Full Text] [Related]
49. [Replacement of dogs as research animals for the approval testing of plant protection products]. Box RJ ALTEX; 2006; 23(1):24-7. PubMed ID: 16477345 [TBL] [Abstract][Full Text] [Related]
50. [Toxicology animal studies necessary for clinical research and registration of drugs for human use: conclusions of the International Harmonization Conference (I)]. Rubio Terrés C; Duque I; Tristán C; Galende I Med Clin (Barc); 1993 Nov; 101(18):705-16. PubMed ID: 8114529 [No Abstract] [Full Text] [Related]
51. Toxicology and Carcinogenesis Studies of Mercuric Chloride (CAS No. 7487-94-7) in F344 Rats and B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1993 Feb; 408():1-260. PubMed ID: 12621522 [TBL] [Abstract][Full Text] [Related]
52. The value and significance of life span and scheduled termination data in long-term toxicity and carcinogenesis studies. Solleveld HA; McConnell EE Toxicol Pathol; 1985; 13(2):128-34. PubMed ID: 4048767 [TBL] [Abstract][Full Text] [Related]
53. Procedures and methods of benefit assessments for medicines in Germany. Bekkering GE; Kleijnen J Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905 [TBL] [Abstract][Full Text] [Related]
54. Analysis of the ToxCast Chemical-Assay Space Using the Comparative Toxicogenomics Database. Hu B; Gifford E; Wang H; Bailey W; Johnson T Chem Res Toxicol; 2015 Nov; 28(11):2210-23. PubMed ID: 26505644 [TBL] [Abstract][Full Text] [Related]
55. Nonclinical safety of ziconotide: an intrathecal analgesic of a new pharmaceutical class. Skov MJ; Beck JC; de Kater AW; Shopp GM Int J Toxicol; 2007; 26(5):411-21. PubMed ID: 17963128 [TBL] [Abstract][Full Text] [Related]
56. A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions. Ewart L; Milne A; Adkins D; Benjamin A; Bialecki R; Chen Y; Ericsson AC; Gardner S; Grant C; Lengel D; Lindgren S; Lowing S; Marks L; Moors J; Oldman K; Pietras M; Prior H; Punton J; Redfern WS; Salmond R; Skinner M; Some M; Stanton A; Swedberg M; Finch J; Valentin JP J Pharmacol Toxicol Methods; 2013; 68(1):30-43. PubMed ID: 23665080 [TBL] [Abstract][Full Text] [Related]
57. Proposal for international guidelines for reproductive and developmental toxicity testing for pharmaceuticals. Lumley CE Adverse Drug React Toxicol Rev; 1991; 10(3):143-53. PubMed ID: 1747441 [TBL] [Abstract][Full Text] [Related]
58. Standardized electroretinography in primates: a non-invasive preclinical tool for predicting ocular side effects in humans. Bee WH Curr Opin Drug Discov Devel; 2001 Jan; 4(1):81-91. PubMed ID: 11727327 [TBL] [Abstract][Full Text] [Related]
59. An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension. Owen K; Cross DM; Derzi M; Horsley E; Stavros FL Regul Toxicol Pharmacol; 2012 Oct; 64(1):95-103. PubMed ID: 22683289 [TBL] [Abstract][Full Text] [Related]
60. Perspective of humanized mouse models for assessing PK/PD and toxic profile of drug candidates in preclinical study. Chiba K Drug Metab Pharmacokinet; 2014; 29(1):1-2. PubMed ID: 24573168 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]